Abstract 2452
Background
Circulating tumor DNA (ctDNA) has been known to be released from tumor cells and evaluated as potential biomarkers for therapeutic responses. In our previous study, we proved applicability for KRAS mutation as a prognostic marker in pancreatic ductal adenocarcinoma (PDA) through the quantitative analysis of ctDNA using KRAS multiplex kit which covers 7 sites. In this study, we analyzed distribution of each single mutation in tumor and ctDNA by performed droplet digital PCR (ddPCR).
Methods
Total of 126 PDA patients were enrolled and analyzed for tumor DNA. We found 94 patients have samples for matched ctDNA analysis. Plasma was separated by established method and ctDNA were extracted using QIAamp Circulating Nucleic Acid Kit. QX200 Droplet Digital PCR System was applied to measure frequency of KRAS mutations using KRAS screening multiplex kit and probe for G12D, G12V and G12C in ctDNA and tumor DNA. Then, we compared the frequency between multiplex and single point mutation of KRAS.
Results
The positivity of mutation of tumor and ctDNA in multiplex ddPCR were 96.0% (n = 121/126) and 60.3% (n = 76/126), respectively. Positive rates of G12D, G12V and G12C were 59.6%, 24.5% and 22.3% in tumor and 36.2%, 16.0% and 17.0% in ctDNA, respectively. There was a correlation between multiplex and the sum of single point mutation (r = 0.805). In the single point mutation results, 44 of the samples detected in both tumor and ctDNA mutations were detected in the same site (75.9%), 12 of them were partially identical (19.0%), and 3 were inconsistent (5.2%). Comparing the frequency with other studies, G12D and G12V showed no difference in frequency, but G12C showed a higher positive rate than the previous studies even though we did not analysis for G12R. Multiple KRAS mutations were found in 17% and 6.4% in tumor and ctDNA.
Conclusions
These results show that the frequency of KRAS mutation correlated with tumor tissue and ctDNA. Also multiple mutations were detected high proportion compared to the previous studies. Further studies are needed to determine G12R proportion. We further evaluate whether the single point mutation detected by single probe is more valuable than sum of mutations from KRAS multiplex kit as a biomarker for predicting the prognosis of PDA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun-Young Kong.
Funding
National Cancer Center and the Ministry of Health & Welfare, Republic of Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3489 - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study
Presenter: Catherine Marshall
Session: Poster Display session 3
Resources:
Abstract
4606 - ARCHES – the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Presenter: Arnulf Stenzl
Session: Poster Display session 3
Resources:
Abstract
2975 - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).
Presenter: Orazio Caffo
Session: Poster Display session 3
Resources:
Abstract
2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
Presenter: Alicia Morgans
Session: Poster Display session 3
Resources:
Abstract
2134 - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial
Presenter: Janet Brown
Session: Poster Display session 3
Resources:
Abstract
3504 - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents – a meta-analysis of randomized controlled trials.
Presenter: Rodrigo Coutinho Mariano
Session: Poster Display session 3
Resources:
Abstract
2342 - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA
Presenter: Nicolas Delanoy
Session: Poster Display session 3
Resources:
Abstract
5331 - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Presenter: Holger Palmedo
Session: Poster Display session 3
Resources:
Abstract
2823 - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
1500 - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Presenter: Harriet Mintz
Session: Poster Display session 3
Resources:
Abstract